Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real world study on prevalence, treatment and economic burden of myasthenia gravis in Italy.
Antonini G, Habetswallner F, Inghilleri M, Mantegazza R, Rodolico C, Saccà F, Sgarzi M, deRuyck F, Paci S, Phillips G, Crippa L, Veronesi C, Perrone V, Degli Esposti L; LHU study group. Antonini G, et al. Among authors: habetswallner f. Heliyon. 2023 May 20;9(6):e16367. doi: 10.1016/j.heliyon.2023.e16367. eCollection 2023 Jun. Heliyon. 2023. PMID: 37274644 Free PMC article.
Italian recommendations for the diagnosis and treatment of myasthenia gravis.
Evoli A, Antonini G, Antozzi C, DiMuzio A, Habetswallner F, Iani C, Inghilleri M, Liguori R, Mantegazza R, Massa R, Pegoraro E, Ricciardi R, Rodolico C. Evoli A, et al. Among authors: habetswallner f. Neurol Sci. 2019 Jun;40(6):1111-1124. doi: 10.1007/s10072-019-03746-1. Epub 2019 Feb 18. Neurol Sci. 2019. PMID: 30778878
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.
Bril V, Drużdż A, Grosskreutz J, Habib AA, Mantegazza R, Sacconi S, Utsugisawa K, Vissing J, Vu T, Boehnlein M, Bozorg A, Gayfieva M, Greve B, Woltering F, Kaminski HJ; MG0003 study team. Bril V, et al. Lancet Neurol. 2023 May;22(5):383-394. doi: 10.1016/S1474-4422(23)00077-7. Lancet Neurol. 2023. PMID: 37059507 Clinical Trial.
Impact of 2021 European Academy of Neurology/Peripheral Nerve Society diagnostic criteria on diagnosis and therapy of chronic inflammatory demyelinating polyradiculoneuropathy variants.
De Lorenzo A, Liberatore G, Doneddu PE, Manganelli F, Cocito D, Briani C, Fazio R, Mazzeo A, Schenone A, Di Stefano V, Cosentino G, Marfia GA, Benedetti L, Carpo M, Filosto M, Antonini G, Clerici AM, Luigetti M, Matà S, Rosso T, Lucchetta M, Siciliano G, Lauria Pinter G, Cavaletti G, Inghilleri M, Cantisani T, Notturno F, Ricciardi D, Habetswallner F, Spina E, Peci E, Salvalaggio A, Falzone Y, Strano C, Gentile L, Vegezzi E, Mataluni G, Cotti Piccinelli S, Leonardi L, Romano A, Nobile-Orazio E; Italian CIDP Database Study Group. De Lorenzo A, et al. Among authors: habetswallner f. Eur J Neurol. 2024 Apr;31(4):e16190. doi: 10.1111/ene.16190. Epub 2024 Jan 2. Eur J Neurol. 2024. PMID: 38165011
Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST).
Lattanzi S, Canafoglia L, Canevini MP, Casciato S, Chiesa V, Dainese F, De Maria G, Didato G, Falcicchio G, Fanella M, Ferlazzo E, Fisco G, Gangitano M, Giallonardo AT, Giorgi FS, La Neve A, Mecarelli O, Montalenti E, Piazza F, Pulitano P, Quarato PP, Ranzato F, Rosati E, Tassi L, Di Bonaventura C; BRIVAFIRST Group Membership. Lattanzi S, et al. CNS Drugs. 2021 Dec;35(12):1289-1301. doi: 10.1007/s40263-021-00856-3. Epub 2021 Sep 2. CNS Drugs. 2021. PMID: 34476770 Free PMC article. Clinical Trial.
Brivaracetam as add-on treatment in patients with post-stroke epilepsy: real-world data from the BRIVAracetam add-on First Italian netwoRk Study (BRIVAFIRST).
Lattanzi S, Canafoglia L, Canevini MP, Casciato S, Irelli EC, Chiesa V, Dainese F, De Maria G, Didato G, Gennaro GD, Falcicchio G, Fanella M, Ferlazzo E, Gangitano M, La Neve A, Mecarelli O, Montalenti E, Morano A, Piazza F, Pizzanelli C, Pulitano P, Ranzato F, Rosati E, Tassi L, Di Bonaventura C; BRIVAFIRST Group Membership. Lattanzi S, et al. Seizure. 2022 Apr;97:37-42. doi: 10.1016/j.seizure.2022.03.007. Epub 2022 Mar 10. Seizure. 2022. PMID: 35320736 Free article.
Brivaracetam as Early Add-On Treatment in Patients with Focal Seizures: A Retrospective, Multicenter, Real-World Study.
Lattanzi S, Canafoglia L, Canevini MP, Casciato S, Cerulli Irelli E, Chiesa V, Dainese F, De Maria G, Didato G, Di Gennaro G, Falcicchio G, Fanella M, Ferlazzo E, Gangitano M, La Neve A, Mecarelli O, Montalenti E, Morano A, Piazza F, Pizzanelli C, Pulitano P, Ranzato F, Rosati E, Tassi L, Di Bonaventura C; BRIVAracetam add-on First Italian netwoRk Study (BRIVAFIRST) Group. Lattanzi S, et al. Neurol Ther. 2022 Dec;11(4):1789-1804. doi: 10.1007/s40120-022-00402-3. Epub 2022 Sep 16. Neurol Ther. 2022. PMID: 36109431 Free PMC article.
Economic evaluation of subcutaneous versus intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy: a real-life study.
Piscitelli E, Massa M, De Martino BM, Serio CS, Guglielmi G, Colacicco G, Tuccillo F, Habetswallner F. Piscitelli E, et al. Among authors: habetswallner f. Eur J Hosp Pharm. 2021 Nov;28(Suppl 2):e115-e119. doi: 10.1136/ejhpharm-2020-002430. Epub 2020 Oct 29. Eur J Hosp Pharm. 2021. PMID: 33122403 Free PMC article.
Adjunctive Brivaracetam in Older Patients with Focal Seizures: Evidence from the BRIVAracetam add‑on First Italian netwoRk Study (BRIVAFIRST).
Lattanzi S, Canafoglia L, Canevini MP, Casciato S, Cerulli Irelli E, Chiesa V, Dainese F, De Maria G, Didato G, Falcicchio G, Fanella M, Ferlazzo E, Gangitano M, Giorgi FS, La Neve A, Mecarelli O, Montalenti E, Morano A, Piazza F, Pulitano P, Quarato PP, Ranzato F, Rosati E, Tassi L, Di Bonaventura C; BRIVAFIRST Group Membership. Lattanzi S, et al. Drugs Aging. 2022 Apr;39(4):297-304. doi: 10.1007/s40266-022-00931-4. Epub 2022 Mar 28. Drugs Aging. 2022. PMID: 35344198 Free PMC article.
33 results